Results 131 to 140 of about 81,525 (242)

Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain

Journal of Pain Research, 2015
Ish K Khanna, Sivaram PillarisettiNeuroPn Therapeutics, Alpharetta, GA, USAAbstract: Despite proven clinical utility, buprenorphine has not been used widely for the treatment of chronic pain.
Khanna IK, Pillarisetti S
doaj  

Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl

Addiction Science & Clinical Practice
Background In response to greater illicit fentanyl use, buprenorphine daily doses exceeding the FDA’s recommended target daily dose (16 mg) and maximum suggested daily dose (24 mg) may provide better outcomes, but little is known about higher dosage ...
Bradley D. Stein, Flora Sheng, Brendan K. Saloner, Adam J. Gordon, Jessica S. Merlin   +4 more
doaj   +1 more source

Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the Treatment of Neonatal Abstinence Syndrome [PDF]

, 2017
Neonatal abstinence syndrome (NAS) is a condition affecting newborns exposed to an opioid in utero. Symptoms of NAS include excessive crying, poor feeding, and disordered autonomic control.
Adeniyi-Jones, MD, Susan C., Gastonguay, Marc, Kraft, MD, FACP, Walter K., Moody, David E., Moore, PharmD, Jason N.   +4 more
core   +1 more source

Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). [PDF]

, 2019
Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants develop after intrauterine maternal drug exposure. All infants with documented in utero opioid exposure, or a high pre-test probability of exposure should have ...
Kraft, W. K., Mangat, A. K., Schmölzer, G. M.   +2 more
core   +1 more source

Ketamine-assisted buprenorphine initiation: a pilot case series

Addiction Science & Clinical Practice
Background Many people with opioid use disorder who stand to benefit from buprenorphine treatment are unwilling to initiate it due to experience with or fear of both spontaneous and buprenorphine-precipitated opioid withdrawal (BPOW).
Lucinda A. Grande, Tom Hutch, Keira Jack, Wendy Mironov, Jessica Iwuoha, Martin Muy-Rivera, Jacob Grillo, Stephen A. Martin, Andrew Herring   +8 more
doaj   +1 more source

Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. [PDF]

, 2018
BACKGROUND: Methadone and buprenorphine are recommended to treat opioid use disorders during pregnancy. However, the literature on the relationship between longer-term effects of prenatal exposure to these medications and childhood development is both ...
Coyle, Mara G., Fischer, Gabriele, Heil, Sarah H., Jones, Hendrée E., Kaltenbach, Karol, Martin, Peter R., O\u27Grady, Kevin E, Salisbury, Amy L., Stine, Susan   +8 more
core   +1 more source

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone

Substance Abuse and Rehabilitation, 2015
Michael Soyka1,21Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität, Munich, Germany; 2Private Hospital Meiringen, Meiringen, SwitzerlandAbstract: Opioid maintenance therapy is a well-established first-line treatment approach
Soyka M
doaj  

Managing Acute Surgical Pain in Patients on Buprenorphine: A Case-Based Learning Module. [PDF]

Orthop Rev (Pavia)
Hasoon J, Nguyen A, Robinson CL.
europepmc   +1 more source

Buprenorphine utilization following removal of prior authorization requirements in the Kentucky Medicaid population. [PDF]

Drug Alcohol Depend
Miracle DK, Hammerslag LR, Slavova S, Lofwall MR, Walsh SL, Talbert J, Freeman PR.   +6 more
europepmc   +1 more source

Barriers to Buprenorphine Prescribing for Opioid Use Disorder Among Louisiana Family Physicians: A Pilot Survey Study With Narrative Review. [PDF]

Cureus
Pippin M.
europepmc   +1 more source